ERBB2 and breast carcinoma: Trastuzumab (Herceptin) is a well-recognized humanized anti-HER2 monoclonal antibody that directly targets the extracellular ligand-binding region of HER2 and has been successfully applied to cure early-stage and metastatic HER2-overexpressing breast cancer [75].